1-18 of 18
Daniel M. Sullivan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, Jeffrey E. Lancet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 54–60.
https://doi.org/10.1158/1078-0432.CCR-19-2169
Published: 03 January 2020
View article titled, Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Open the PDF for Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Lesley Seymour, Susan Groshen, Gary L. Rosner, Daniel M. Sullivan, David R. Spriggs, Steven Reeves, Amy Gravell, S. Percy Ivy, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5057–5063.
https://doi.org/10.1158/1078-0432.CCR-15-0035
Published: 12 November 2015
View article titled, Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Open the PDF for Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee in another window
Journal Articles

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Jr, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor, III, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1574–1582.
https://doi.org/10.1158/1078-0432.CCR-14-2565
Published: 31 March 2015
View article titled, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer
Open the PDF for Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Timothy A. Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearen, Kyriakos P. Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A. Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P. Heaton, Karen Swales, Nandita M. deSouza, Martin O. Leach, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5672–5685.
https://doi.org/10.1158/1078-0432.CCR-14-0868
Published: 13 November 2014
View article titled, Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Open the PDF for Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Janelle B. Perkins, Steven C. Goldstein, Jana L. Dawson, Jongphil Kim, Teresa L. Field, James S. Partyka, Karen K. Fields, Beth L. Maddox, Christine E. Simonelli, Anthony M. Neuger, Richard M. Lush, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7743–7753.
https://doi.org/10.1158/1078-0432.CCR-11-1540
Published: 18 December 2011
View article titled, Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
Open the PDF for Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3388–3397.
https://doi.org/10.1158/1078-0432.CCR-10-2876
Published: 15 May 2011
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

Jeffrey E. Lancet, Vu H. Duong, Elliott F. Winton, Robert K. Stuart, Michelle Burton, Shumin Zhang, Christopher Cubitt, Michelle A. Blaskovich, John J. Wright, Said Sebti, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1140–1146.
https://doi.org/10.1158/1078-0432.CCR-10-1878
Published: 01 March 2011
View article titled, A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
Open the PDF for A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias in another window
Journal Articles

The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally

William S. Dalton, Daniel M. Sullivan, Timothy J. Yeatman, David A. Fenstermacher
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 5987–5996.
https://doi.org/10.1158/1078-0432.CCR-10-1216
Published: 16 December 2010
View article titled, The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally
Open the PDF for The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally in another window
Journal Articles

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Adil I. Daud, Jana Dawson, Ronald C. DeConti, Elona Bicaku, Douglas Marchion, Sem Bastien, Frederick A. Hausheer, III, Richard Lush, Anthony Neuger, Daniel M. Sullivan, Pamela N. Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2479–2487.
https://doi.org/10.1158/1078-0432.CCR-08-1931
Published: 01 April 2009
View article titled, Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Open the PDF for Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Jade Homsi, George R. Simon, Chris R. Garrett, Gregory Springett, Ronald De Conti, Alberto A. Chiappori, Pamela N. Munster, Michelle K. Burton, Scott Stromatt, Claudia Allievi, Patrizia Angiuli, Amy Eisenfeld, Daniel M. Sullivan, Adil I. Daud
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5855–5861.
https://doi.org/10.1158/1078-0432.CCR-06-2821
Published: 01 October 2007
View article titled, Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

Alberto A. Chiappori, S. Gail Eckhardt, Ronald Bukowski, Daniel M. Sullivan, Minoru Ikeda, Yoshitaka Yano, Takuko Yamada-Sawada, Yoshikaze Kambayashi, Kazushige Tanaka, Milind M. Javle, Tarek Mekhail, Cindy L. O'Bryant, Patrick J. Creaven
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2091–2099.
https://doi.org/10.1158/1078-0432.CCR-06-1586
Published: 02 April 2007
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors in another window
Journal Articles

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Paula M. Fracasso, Howard Burris, III, Matthew A. Arquette, Ramaswamy Govindan, Feng Gao, Lisa P. Wright, Sherry A. Goodner, F. Anthony Greco, Suzanne F. Jones, Noel Willcut, Catherine Chodkiewicz, Amit Pathak, Gregory M. Springett, George R. Simon, Daniel M. Sullivan, Raphaël Marcelpoil, Shelley D. Mayfield, David Mauro, Christopher R. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 986–993.
https://doi.org/10.1158/1078-0432.CCR-06-1542
Published: 08 February 2007
View article titled, A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Open the PDF for A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing in another window
Journal Articles

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

George R. Simon, Christopher R. Garrett, Stephen C. Olson, Michael Langevin, Irene A. Eiseman, John J. Mahany, Charles C. Williams, Richard Lush, Adil Daud, Pamela Munster, Alberto Chiappori, Mayer Fishman, Gerold Bepler, Peter F. Lenehan, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4645–4651.
https://doi.org/10.1158/1078-0432.CCR-05-2379
Published: 09 August 2006
View article titled, Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
Open the PDF for Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study in another window
Journal Articles

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Mayer N. Fishman, Christopher R. Garrett, George R. Simon, Alberto A. Chiappori, Richard M. Lush, William R. Dinwoodie, J. Joseph Mahany, Anne M. Dellaportas, Alan Cantor, Ashwin Gollerki, Marvin B. Cohen, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 523–528.
https://doi.org/10.1158/1078-0432.CCR-05-0928
Published: 20 January 2006
View article titled, Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies
Open the PDF for Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies in another window
Journal Articles

Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ

Douglas C. Marchion, Elona Bicaku, Joel G. Turner, Adil I. Daud, Daniel M. Sullivan, Pamela N. Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8467–8475.
https://doi.org/10.1158/1078-0432.CCR-05-1073
Published: 01 December 2005
View article titled, Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ
Open the PDF for Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ in another window
Journal Articles

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Christopher R. Garrett, Mayer N. Fishman, Randall R. Rago, Charles C. Williams, Anne M. Dellaportas, J. Joseph Mahany, Richard M. Lush, William S. Dalton, Ashwin Gollerkeri, Marvin B. Cohen, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3335–3341.
https://doi.org/10.1158/1078-0432.CCR-04-1494
Published: 02 May 2005
View article titled, Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies
Open the PDF for Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies in another window
Journal Articles

A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors

Stacy L. Moulder, John J. Mahany, Richard Lush, Caio Rocha-Lima, Michael Langevin, Karen J. Ferrante, Lisa Michele Bartkowski, Shama M. Kajiji, Dennis A. Noe, Simone Paillet, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7127–7135.
https://doi.org/10.1158/1078-0432.CCR-04-0901
Published: 08 November 2004
View article titled, A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Open the PDF for A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors in another window